Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaRe2THINK
ISRCTN21157803Phase 4Recruiting
- Sponsor
- University of Birmingham
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of apixaban, dabigatran, edoxaban and rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by University of Birmingham. Primary endpoints: Time to first event of cardiovascular mortality, Time to first ischaemic cerebrovascular event and 3 more. Started Jun 2021; status: recruiting.
02
Drugs
apixabandabigatranedoxabanrivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ISRCTN21157803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21157803.